The purpose of this study is to identify a dose of P276-00 that can be safely administered
along with Gemcitabine and to examine safety and efficacy of the combination in treatment of
advanced pancreatic cancer.
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT00898287
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Histologically or cytologically confirmed diagnosis of infiltrating ductal adenocarcinoma of pancreas.
Chemonaive patients i.e. patients must not have received chemotherapy or biologic/targeted anticancer therapy for the adenocarcinoma of pancreas.
Locally advanced inoperable pancreatic cancer.
Patients of either sex, aged > or = 18 years.
Karnofsky performance status of > or = 60%.
Adequate bone marrow reserve: white blood cell (WBC) count > or = 4 x 109/l, Absolute neutrophil count (ANC) ≥ 1.5 x 109/l, platelets > or = 100 x 109/l, hemoglobin > or = 10 g/dl.
Adequate liver function: bilirubin < or = 1.5 times the upper normal value, ALT/AST/ alkaline phosphatase less than 3 times the upper normal value (unless due to liver metastases in which case bilirubin less than 3 times the upper normal value, ALT/AST less than 4 times the upper normal value, and alkaline phosphatase without limit).
Adequate renal function: creatinine ≤ 1.5 times the upper normal value.
Childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of at least 2 approved contraceptive methods (at least one should be a barrier method) during and for 4 weeks after stopping the study treatment.
Negative urine β-HCG test within 1 week prior to protocol entry where childbearing potential is not terminated.
Additional inclusion criterion only for part B: Patient should satisfy at least one of the following criteria on cycle 1 day 1:
Karnofsky performance status of 60 or 70
Baseline pain intensity score of > or = 20 mm
Inability / unwillingness to give consent.
Pregnant or breast feeding women.
Brain metastasis (active or inactive).
Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).
Patients known to be suffering from infection with HIV, Hepatitis C or Hepatitis B.
Patients who had received any other investigational drug within 1 month prior to Day 1 of protocol treatment.
Patients with QTc > 450 msec on 12-lead standard electrocardiogram (ECG).
Major surgery within 2 weeks prior to protocol treatment.
Radiotherapy to > 10% of bone marrow.
Patients with 3rd space fluid accumulation (ascites, pleural effusion).
All locations for NCT00898287
Central India Cancer Research Institute
Nagpur, Ajayonco@hotmail.com, India, 440 010
Hyderabaad, Andhra Pradesh, India, 500004
Curie Manavata Cancer Centre
Nashik, Maharashtra, India, 422 004
Deenanath Mangeshkar Hospital & Research Centre
Pune, Maharashtra, India, 411004
Sri RamaChandra Medical Centre
Chennai, Tamil Nadu, India, 600 116
Lifeline Mutispecilaity Hospital
Chennai, Tamil Nadu, India, 600096
Meenakshi Mission Hospital & Reasearch Centre
Madurai, Tamil Nadu, India, 625107
View full eligibility
Tris trial is registered with FDA with number: NCT00898287. The sponsor of the trial is Piramal Enterprises Limited and it is looking for 23 volunteers for the current phase.
Official trial title: A Phase I/II Study to Evaluate Safety and Efficacy of P276-00 in Combination With Gemcitabine in Patients With Cancer of Pancreas
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
FindMeCure is constantly improving its search. Take part in it and help millions by filling our patients' survey!